|
CH637297A5
(fr)
*
|
1978-12-05 |
1983-07-29 |
Nestle Sa |
Microbille comprenant un microorganisme et son procede de fabrication.
|
|
US4421736A
(en)
*
|
1982-05-20 |
1983-12-20 |
Merrel Dow Pharmaceuticals Inc. |
Sustained release diethylpropion compositions
|
|
US4507276A
(en)
*
|
1982-08-20 |
1985-03-26 |
Bristol-Myers Company |
Analgesic capsule
|
|
FR2548021B1
(fr)
*
|
1983-06-29 |
1986-02-28 |
Dick P R |
Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels
|
|
NL8500724A
(nl)
*
|
1985-03-13 |
1986-10-01 |
Univ Groningen |
Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.
|
|
US4755387A
(en)
*
|
1985-03-21 |
1988-07-05 |
The Procter & Gamble Company |
Therapeutic particles
|
|
US4874614A
(en)
*
|
1985-03-25 |
1989-10-17 |
Abbott Laboratories |
Pharmaceutical tableting method
|
|
US4863741A
(en)
*
|
1985-03-25 |
1989-09-05 |
Abbott Laboratories |
Tablet composition for drug combinations
|
|
CA1279574C
(en)
*
|
1985-04-17 |
1991-01-29 |
Jeffrey L. Finnan |
Process for lubricating water-soluble vitamin powders
|
|
US4728512A
(en)
*
|
1985-05-06 |
1988-03-01 |
American Home Products Corporation |
Formulations providing three distinct releases
|
|
US4794001A
(en)
*
|
1986-03-04 |
1988-12-27 |
American Home Products Corporation |
Formulations providing three distinct releases
|
|
US4904476A
(en)
*
|
1986-03-04 |
1990-02-27 |
American Home Products Corporation |
Formulations providing three distinct releases
|
|
US5019302A
(en)
*
|
1986-03-12 |
1991-05-28 |
Washington University Technology Associates, Inc. |
Method for granulation
|
|
SE8701479L
(sv)
*
|
1987-04-09 |
1988-10-10 |
Carbomatrix Ab |
Metod foer inneslutning av biologiskt verksamma preparat samt anvaendning daerav
|
|
FI77573C
(fi)
*
|
1987-05-08 |
1989-04-10 |
Orion Yhtymae Oy |
Ny konsistens.
|
|
JP2668880B2
(ja)
*
|
1987-06-23 |
1997-10-27 |
日本油脂株式会社 |
被覆アミノ酸類の製造方法
|
|
DE3721721C1
(de)
*
|
1987-07-01 |
1988-06-09 |
Hoechst Ag |
Verfahren zur Umhuellung von Granulaten
|
|
US5133974A
(en)
*
|
1989-05-05 |
1992-07-28 |
Kv Pharmaceutical Company |
Extended release pharmaceutical formulations
|
|
US5328697A
(en)
*
|
1992-02-10 |
1994-07-12 |
Mallinckrodt Veterinary, Inc. |
Compositions and processes for the sustained release of drugs
|
|
PT1382339E
(pt)
|
1999-12-10 |
2008-02-06 |
Pfizer Prod Inc |
Composições que contêm derivados de pirrolo[2,3-d]- pirimidina
|
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
|
PL358618A1
(pl)
*
|
2000-03-31 |
2004-08-09 |
Pfizer Products Inc. |
Nowe pochodne piperazyny
|
|
US20020068078A1
(en)
*
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
|
AP2001002306A0
(en)
*
|
2000-10-19 |
2001-12-31 |
Pfizer Prod Inc |
Bridged piperazine derivatives.
|
|
OA12623A
(en)
|
2001-06-20 |
2006-06-12 |
Pfizer Prod Inc |
Novel sulfonic acid derivatives.
|
|
EP1438298B1
(en)
*
|
2001-10-22 |
2010-01-27 |
Pfizer Products Inc. |
Piperazine derivatives with ccr1 receptor antagonist activity
|
|
JP2005530775A
(ja)
*
|
2002-05-14 |
2005-10-13 |
ファイザー・プロダクツ・インク |
ジヒドロキシヘキサン酸誘導体、それらの中間体、および製法
|
|
BR0309932A
(pt)
*
|
2002-05-14 |
2005-02-09 |
Pfizer Prod Inc |
Métodos para a fabricação de derivados de diidro-furan-2-ona
|
|
PA8575901A1
(es)
*
|
2002-07-18 |
2004-07-20 |
Pfizer Prod Inc |
Derivados de piperidina novedosos
|
|
CA2494776A1
(en)
*
|
2002-08-12 |
2004-02-19 |
Pfizer Products Inc. |
Crystal forms of quinoxaline-2-carboxylic acid ¬4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl|-amide
|
|
PL375979A1
(en)
|
2002-09-18 |
2005-12-12 |
Pfizer Products Inc. |
Pyrazole derivatives as transforming growth factor (tgf) inhibitors
|
|
US20040087571A1
(en)
*
|
2002-10-30 |
2004-05-06 |
Pfizer Inc |
Methods of using CCR1 antagonists as immunomodulatory agents
|
|
US20040116441A1
(en)
*
|
2002-10-30 |
2004-06-17 |
Pfizer Inc |
Methods of using sulfonic acid derivatives
|
|
US20040097554A1
(en)
*
|
2002-10-30 |
2004-05-20 |
Pfizer Inc |
Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
|
|
KR100678800B1
(ko)
*
|
2002-11-21 |
2007-02-05 |
화이자 프로덕츠 인코포레이티드 |
3-아미노-피페리딘 유도체 및 그의 제조 방법
|
|
WO2004047843A1
(en)
*
|
2002-11-26 |
2004-06-10 |
Pfizer Products Inc. |
Method of treatment of transplant rejection
|
|
CA2505979A1
(en)
*
|
2002-12-13 |
2004-07-01 |
Pfizer Products Inc. |
Phosphorus-containing piperazine derivatives as ccr1 antagonists
|
|
PA8591801A1
(es)
|
2002-12-31 |
2004-07-26 |
Pfizer Prod Inc |
Inhibidores benzamidicos del receptor p2x7.
|
|
ES2264795T3
(es)
*
|
2003-02-14 |
2007-01-16 |
Pfizer Products Inc. |
Triazolo-piridinas como compuestos antiinflamatorios.
|
|
PA8595001A1
(es)
*
|
2003-03-04 |
2004-09-28 |
Pfizer Prod Inc |
Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
|
|
JP2006519833A
(ja)
|
2003-03-11 |
2006-08-31 |
ファイザー・プロダクツ・インク |
トランスフォーミング成長因子（ｔｇｆ）阻害剤としてのピラジン化合物
|
|
US20050119275A1
(en)
*
|
2003-06-24 |
2005-06-02 |
Pfizer Inc. |
Salt and crystal forms of (5-chloro-2-{2-[4-(4-fluoro-benzyl)-(2R,5S)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-methanesulfonic acid
|
|
CA2545192A1
(en)
*
|
2003-11-25 |
2005-06-09 |
Pfizer Products Inc. |
Method of treatment of atherosclerosis
|
|
TW201038578A
(en)
|
2009-01-30 |
2010-11-01 |
Univ Rutgers |
Methods to treat cancer
|
|
US8461102B2
(en)
*
|
2010-03-02 |
2013-06-11 |
George E. Royster, JR. |
Methods and compositions for treating and preventing symptoms of hormonal variations
|
|
MY173998A
(en)
|
2011-03-18 |
2020-03-03 |
Genzyme Corp |
Glucosylceramide synthase inhibitors
|
|
KR20200016407A
(ko)
|
2011-05-16 |
2020-02-14 |
젠자임 코포레이션 |
Ｃｘｃｒ４ 길항제의 용도
|
|
WO2013037065A1
(en)
|
2011-09-13 |
2013-03-21 |
Ottawa Hospital Research Institute |
Microrna inhibitors
|
|
JOP20130273B1
(ar)
|
2012-09-11 |
2021-08-17 |
Genzyme Corp |
مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
|
|
EP2970206A1
(en)
|
2013-03-13 |
2016-01-20 |
Boston Biomedical, Inc. |
3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
|
|
CA2926361A1
(en)
|
2013-10-24 |
2015-04-30 |
Abbvie Inc. |
Jak1 selective inhibitor and uses thereof
|
|
EP3174859B1
(en)
|
2014-07-31 |
2020-04-29 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Flt3 receptor antagonists
|
|
MA41202A
(fr)
|
2014-12-18 |
2017-10-24 |
Genzyme Corp |
Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
|
|
US20180237424A1
(en)
|
2015-03-03 |
2018-08-23 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Fgfr3 antagonists
|
|
TW201642855A
(zh)
|
2015-03-10 |
2016-12-16 |
健臻公司 |
用於治療蛋白質病變之方法
|
|
US12365689B2
(en)
|
2015-10-16 |
2025-07-22 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
KR20250010141A
(ko)
|
2015-10-16 |
2025-01-20 |
애브비 인코포레이티드 |
(3S,4R)-3-에틸-4-(3H-이미다조[1,2-a]피롤로[2,3-e]-피라진-8-일)-N-(2,2,2-트리플루오로에틸)피롤리딘-1-카복스아미드및 이의 고체상 형태의 제조 방법
|
|
US12570664B2
(en)
|
2015-10-16 |
2026-03-10 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US10076494B2
(en)
|
2016-06-16 |
2018-09-18 |
Dexcel Pharma Technologies Ltd. |
Stable orally disintegrating pharmaceutical compositions
|
|
CA3029889A1
(en)
|
2016-07-08 |
2018-01-11 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
4-anilino-quinoline compounds as anti-cancer agents
|
|
EP3735408B1
(en)
|
2018-01-05 |
2023-11-29 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Substituted halo-quinoline derivatives, method of preparation and applications thereof
|
|
TWI853841B
(zh)
|
2018-10-03 |
2024-09-01 |
美商提薩羅有限公司 |
尼拉帕尼（niraparib）鹽
|
|
WO2020072796A1
(en)
|
2018-10-03 |
2020-04-09 |
Tesaro, Inc. |
Crystalline forms of niraparib freebase
|
|
PT3920912T
(pt)
|
2019-02-04 |
2025-09-09 |
Genzyme Corp |
Tratamento de ciliopatias usando inibidores da glucosilceramida sintase (gcs)
|
|
MX2021009384A
(es)
|
2019-02-04 |
2021-09-10 |
Genzyme Corp |
Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico.
|
|
EP4100009A1
(en)
|
2020-02-03 |
2022-12-14 |
Genzyme Corporation |
Methods for treating neurological symptoms associated with lysosomal storage diseases
|
|
CA3186766A1
(en)
|
2020-07-24 |
2022-01-27 |
Danielle Combessis |
Pharmaceutical compositions comprising venglustat
|
|
CN116322663A
(zh)
|
2020-09-30 |
2023-06-23 |
比奥维拉迪维治疗股份有限公司 |
Ampk激活剂及其使用方法
|
|
WO2022140528A1
(en)
|
2020-12-23 |
2022-06-30 |
Genzyme Corporation |
Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
|
|
WO2023196640A1
(en)
|
2022-04-08 |
2023-10-12 |
Bioverativ Therapeutics Inc. |
Oxindole derivatives as ampk activators for use in the treatment of rare blood disorders
|
|
IL321165A
(en)
|
2022-12-01 |
2025-07-01 |
Genzyme Corp |
Vanglustat in combination with a strong or moderate CYP3A4 inhibitor
|
|
WO2025074120A1
(en)
|
2023-10-06 |
2025-04-10 |
Imperial College Innovations Limited |
Nanoparticles for extended release drug delivery
|
|
WO2025262570A1
(en)
|
2024-06-17 |
2025-12-26 |
Genzyme Corporation |
Venglustat as an inhibitor of glucosylceramide synthase in subjects having hepatic impairment
|
|
GB202411975D0
(en)
|
2024-08-14 |
2024-09-25 |
Imperial College Innovations Ltd |
Nanoparticles for extended release drug delivery
|